Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.51 |
| ▸ | CTSD | P07339 | 6/20 | 0.43 |
| ▸ | CTSE | P14091 | 2/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14013471 | 1.00 | BACE1 (0.51) | BACE1CTSDCTSEADRB2ADRB1 | |
| SCHEMBL5098600 | 0.98 | BACE1 (0.52) | BACE1CTSDCTSEADRB2ADRB1 | |
| SCHEMBL14013562 | 0.98 | BACE1 (0.52) | BACE1CTSDCTSEADRB2ADRB1 | |
| SCHEMBL4825081 | 0.92 | BACE1 (0.47) | BACE1CTSDCTSEADRB2ADRB1 | |
| SCHEMBL14017986 | 0.92 | BACE1 (0.47) | BACE1CTSDCTSEADRB2ADRB1 | |
| SCHEMBL14018031 | 0.91 | BACE1 (0.46) | BACE1CTSDCTSEADRB2ADRB1 | |
| SCHEMBL4827388 | 0.91 | BACE1 (0.46) | BACE1CTSDCTSEADRB2ADRB1 | |
| SCHEMBL5105558 | 0.91 | BACE1 (0.54) | BACE1CTSDCTSE | |
| SCHEMBL14013467 | 0.91 | BACE1 (0.54) | BACE1CTSDCTSE | |
| SCHEMBL5110953 | 0.89 | BACE1 (0.55) | BACE1CTSDCTSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456163-B2 | Macrocycles useful in the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | claimed |
| US-7067507-B2 | Macrocycles useful in the treatment of Alzheimer's disease | PHARMACIA & UPJOHN COMPANY (US) | 2006-06-27 | — | — | US | claimed |
| US-20060003978-A1 | Macrocycles useful in the treatment of alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-05 | — | — | US | claimed |
| US-20030236240-A1 | Macrocycles useful in the treatment of alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7456163-B2 | Macrocycles useful in the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7067507-B2 | Macrocycles useful in the treatment of Alzheimer's disease | PHARMACIA & UPJOHN COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060003978-A1 | Macrocycles useful in the treatment of alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003978-A1 | Macrocycles useful in the treatment of alzheimer's disease | BACE1, APP, BACE2 | BACE1 1/4885CTSD 70/4885CTSE 41/4885 |
| US-20030236240-A1 | Macrocycles useful in the treatment of alzheimer's disease | BACE1, APP, PSEN1 | BACE1 1/4885CTSD 97/4885CTSE 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.